Sodium Acetate Injection · 3,873 days since initial FDA posting
Brand: SODIUM ACETATE
FDA lists Sodium Acetate Injection as Active Shortage (Hospira, Inc., a Pfizer Company).
Availability on file: Limited Availability
Sodium Acetate Injection: Active Shortage
Limited Availability Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Sodium Acetate Injection
- Manufacturer
- Hospira, Inc., a Pfizer Company
- Dosage Form
- Injection
- Presentation
- Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06)
- Package NDC
- 0409-3299-06
Status & Timeline
- Status
- Active Shortage
- Availability
- Limited Availability
- First Reported
- Feb 3, 2016
- Last Updated
- Mar 13, 2026
- Therapeutic Category
- Endocrinology/Metabolism, Gastroenterology, Pediatric, Total Parenteral Nutrition
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Limited Supply Available. Next Delivery and Estimated Recovery: March 2026; Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay
Nearby, Other Sodium Shortage Records
Sodium Acetate Injection
Fresenius Kabi USA, LLC
Injection
Sodium Acetate Injection
Milla Pharmaceuticals
Injection
Sodium Acetate Injection
Milla Pharmaceuticals
Injection
Sodium Acetate Injection
Milla Pharmaceuticals
Injection
Sodium Acetate Injection
Hospira, Inc., a Pfizer Company
Injection
Sodium Acetate Injection
Hospira, Inc., a Pfizer Company
Injection
FDA reason on file: Limited Supply Available. General shortage guidance lives on the tracker hub.